Invivyd, Inc.
Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory…
Company newsroom
NASDAQ:IVVD
1 releases
DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory…